New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...

SAN ANTONIO -- Endocrine therapy after breast-conserving surgery was associated with worse health-related quality of life ...

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.

Both radiotherapy and endocrine therapy are good single-modality options for women 70 years or older with early, favorable ...

Treatment with imlunestrant either with or without Verzenio was shown to improve progression-free survival in some with ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

Chinese researchers have revealed new insights into the growth of craniopharyngioma and identified a potential therapeutic ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

B reast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s ...

SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy ...